These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16945954)

  • 1. Tumor inhibition by genomically integrated inducible RNAi-cassettes.
    Kappel S; Matthess Y; Zimmer B; Kaufmann M; Strebhardt K
    Nucleic Acids Res; 2006; 34(16):4527-36. PubMed ID: 16945954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1.
    Matthess Y; Kappel S; Spänkuch B; Zimmer B; Kaufmann M; Strebhardt K
    Oncogene; 2005 Apr; 24(18):2973-80. PubMed ID: 15735719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
    Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of growth inhibition of gastric cancer cells by sRNA targeting polo like kinase 1 in vitro and vivo].
    Lan B; Liu BY; Cheng XH; Qu Y; Zhang XQ; Cai Q; Dai QB; Zhu ZG
    Zhonghua Wai Ke Za Zhi; 2006 Jan; 44(1):40-4. PubMed ID: 16620646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.
    Spänkuch B; Matthess Y; Knecht R; Zimmer B; Kaufmann M; Strebhardt K
    J Natl Cancer Inst; 2004 Jun; 96(11):862-72. PubMed ID: 15173270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
    Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T
    Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi-mediated gene silencing in tumour tissue using replication-competent retroviral vectors.
    Schaser T; Wrede C; Duerner L; Sliva K; Cichutek K; Schnierle B; Buchholz CJ
    Gene Ther; 2011 Oct; 18(10):953-60. PubMed ID: 21472010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced chemosensitivity to CPT-11 in colorectal carcinoma xenografts by small hairpin RNA interference targeting PLK1.
    Fan P; Zhang S; Tian H; Yan N; Dai L; Zhang X; Cheng L; Li C; Li Y; Chen X; Shi G; Yang Y; Wei Y; Deng H
    Neoplasma; 2012; 59(6):676-84. PubMed ID: 22862168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of PLK1 gene silence on apoptosis of K562 cells].
    Zhang M; Chen ZC; Liu F; You Y; Liu ZP; Zou P
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):715-8. PubMed ID: 16620572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
    Cheng MW; Wang BC; Weng ZQ; Zhu XW
    Acta Histochem; 2012 Sep; 114(5):503-9. PubMed ID: 22000864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid functional screening of effective siRNAs against Plk1 and its growth inhibitory effects in laryngeal carcinoma cells.
    Lan H; Zhu J; Ai Q; Yang Z; Ji Y; Hong S; Song F; Bu Y
    BMB Rep; 2010 Dec; 43(12):818-23. PubMed ID: 21189159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway.
    Kim HJ; Cho JH; Kim JR
    J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1145-56. PubMed ID: 23525475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
    Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
    Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
    Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
    Kreis NN; Sommer K; Sanhaji M; Krämer A; Matthess Y; Kaufmann M; Strebhardt K; Yuan J
    Cell Cycle; 2009 Feb; 8(3):460-72. PubMed ID: 19177004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.
    van der Meer R; Song HY; Park SH; Abdulkadir SA; Roh M
    Clin Cancer Res; 2014 Jun; 20(12):3211-21. PubMed ID: 24771642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.